Increasing the use of orphan drugs in clinical practice

Hospital Medicine

Volumn 65, Issue 7, 2004, Pages 400-403

  Hulton, Sally Anne ^a   Greener, Mark ^b  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; CYSTINOSIS; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG PREFERENCE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HAIRY CELL LEUKEMIA; HEMOPHILIA; HUMAN; LICENSING; MEDICOLEGAL ASPECT; OVARY CARCINOMA;

EID: 3242782466     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.7.15455     Document Type: Conference Paper

References (16)

1. Anonymous (2002) Bigger isn't always better. Nature 418: 353
2. Conroy S, Mcintyre J, Choonara I (1999) Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 80: F142-7
3. Conroy S, Choonara I, Impicciatore P et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 320: 79-82
4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10: 107-42
5. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-85
6. European Commission (2002) Better Medicines for Children. Proposed regulatory actions on paediatric medicinal products. Consultation document. European Commission, Brussels (http://europa.eu.int/rapid/pressReleasesAction. do?reference=SPEECH/02/92&format=HTML&aged=0&language- EN&guiLanguage=en; accessed 30 June 2004)
7. European Parliament (1999) European Parliament legislative resolution on the common position established by the Council with a view to the adoption of a European Parliament and Council regulation on orphan medicinal products (9616/1/1999 - C5-0182/1999 1998/0240(COD)). European Parliament, Brussels http://www2.europarl.eu.int/omk/sipade2?PUBREF=-//EP//TEXT+TA+P5-TA-1999- 0127+0+DOC+XML+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y (accessed 30 June 2004).
8. Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev Drug Discov 1: 821-5
9. Lavandeira A (2002) Orphan drugs: legal aspects, current situation. Haemophilia 8: 194-8
10. Lee K, Mills A (2000) Strengthening governance for global health research. BMJ 321: 775-6
11. Milne C-P (2002) Orphan products-pain relief for clinical development headaches. Nat Biotechnol 20: 780-4
12. Nahata MC (1997) Licensing of medicines for children in the USA. Pediatr Perinat Drug Therapy 1: 50-1
13. Pabst JY (2001) Orphan drugs: some legal, ethical and economics aspects. Rev Epidemiol Sante Publique 49: 387-96
14. Schneider JA, Clark KF, Greene AA et al (1995) Recent advances in the treatment of cystinosis. J Int Metab Dis 18: 387-97
15. Turner S, Munn AJ, Choonara I (1997) Unlicensed drug use in children in the UK. Paediatr Perinat Drug Therapy 1: 52-5
16. Walsh G (2003) Biopharmaceutical Benchmarks - 2003. Nat Biotechnol 21: 865-70